# Daniela Giuliani

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 83 papers | 2,804 citations | 32 h-index | 49 g-index |
| 85 ext. papers | 3,029 ext. citations | 5.9 avg, IF | 4.31 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 83 | Oxidative Stress in Alzheimer's Disease: Therapeutic Effect of Amniotic Fluid Stem Cells Extracellular Vesicles. *Oxidative Medicine and Cellular Longevity*, **2020**, 2020, 2785343 | 6.7 | 7 |
| 82 | Mechanisms of Hydrogen Sulfide against the Progression of Severe Alzheimer's Disease in Transgenic Mice at Different Ages. *Pharmacology*, **2019**, 103, 50-60 | 2.3 | 28 |
| 81 | Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy. *Molecular Neurobiology*, **2018**, 55, 1396-1404 | 6.2 | 5 |
| 80 | Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo. *Molecular Neurobiology*, **2018**, 55, 4984-4997 | 6.2 | 1 |
| 79 | Effects of COX1-2/5-LOX blockade in Alzheimer transgenic 3xTg-AD mice. *Inflammation Research*, **2017**, 66, 389-398 | 7.2 | 27 |
| 78 | Multiple beneficial effects of melanocortin MC receptor agonists in experimental neurodegenerative disorders: Therapeutic perspectives. *Progress in Neurobiology*, **2017**, 148, 40-56 | 10.9 | 24 |
| 77 | NDP-□MSH attenuates heart and liver responses to myocardial reperfusion via the vagus nerve and JAK/ERK/STAT signaling. *European Journal of Pharmacology*, **2015**, 769, 22-32 | 5.3 | 11 |
| 76 | NDP-□MSH induces intense neurogenesis and cognitive recovery in Alzheimer transgenic mice through activation of melanocortin MC4 receptors. *Molecular and Cellular Neurosciences*, **2015**, 67, 13-21 | 4.8 | 23 |
| 75 | Protective effects of the melanocortin analog NDP-□MSH in rats undergoing cardiac arrest. *European Journal of Pharmacology*, **2014**, 745, 108-16 | 5.3 | 14 |
| 74 | Melanocortins protect against brain damage and counteract cognitive decline in a transgenic mouse model of moderate Alzheimer?s disease. *European Journal of Pharmacology*, **2014**, 740, 144-50 | 5.3 | 17 |
| 73 | Melanocortins protect against progression of Alzheimer's disease in triple-transgenic mice by targeting multiple pathophysiological pathways. *Neurobiology of Aging*, **2014**, 35, 537-47 | 5.6 | 50 |
| 72 | Modulation of the JAK/ERK/STAT signaling in melanocortin-induced inhibition of local and systemic responses to myocardial ischemia/reperfusion. *Pharmacological Research*, **2013**, 72, 1-8 | 10.2 | 27 |
| 71 | Hydrogen sulfide slows down progression of experimental Alzheimer's disease by targeting multiple pathophysiological mechanisms. *Neurobiology of Learning and Memory*, **2013**, 104, 82-91 | 3.1 | 172 |
| 70 | Up-regulation of the canonical Wnt-3A and Sonic hedgehog signaling underlies melanocortin-induced neurogenesis after cerebral ischemia. *European Journal of Pharmacology*, **2013**, 707, 78-86 | 5.3 | 42 |
| 69 | Centrally acting leptin induces a resuscitating effect in haemorrhagic shock in rats. *Regulatory Peptides*, **2012**, 176, 45-50 | | 3 |
| 68 | Melanocortins as potential therapeutic agents in severe hypoxic conditions. *Frontiers in Neuroendocrinology*, **2012**, 33, 179-93 | 8.9 | 26 |
| 67 | Protective effects of melanocortins on short-term changes in a rat model of traumatic brain injury*. *Critical Care Medicine*, **2012**, 40, 945-51 | 1.4 | 24 |

| | | | |
|---|---|---|---|
| 66 | Molecular changes induced in rat liver by hemorrhage and effects of melanocortin treatment. *Anesthesiology*, **2012**, 116, 692-700 | 4.3 | 10 |
| 65 | Melanocortin 4 receptor activation protects against testicular ischemia-reperfusion injury by triggering the cholinergic antiinflammatory pathway. *Endocrinology*, **2011**, 152, 3852-61 | 4.8 | 23 |
| 64 | Melanocortin 4 receptor stimulation decreases pancreatitis severity in rats by activation of the cholinergic anti-inflammatory pathway. *Critical Care Medicine*, **2011**, 39, 1089-96 | 1.4 | 42 |
| 63 | Melanocortins protect against multiple organ dysfunction syndrome in mice. *British Journal of Pharmacology*, **2011**, 162, 917-28 | 8.6 | 22 |
| 62 | Melanocortin MC receptor agonists counteract late inflammatory and apoptotic responses and improve neuronal functionality after cerebral ischemia. *European Journal of Pharmacology*, **2011**, 670, 479-86 | 5.3 | 40 |
| 61 | Treatment of cerebral ischemia with melanocortins acting at MC4 receptors induces marked neurogenesis and long-lasting functional recovery. *Acta Neuropathologica*, **2011**, 122, 443-53 | 14.3 | 47 |
| 60 | Melanocortins and the cholinergic anti-inflammatory pathway. *Advances in Experimental Medicine and Biology*, **2010**, 681, 71-87 | 3.6 | 23 |
| 59 | Melanocortins counteract inflammatory and apoptotic responses to prolonged myocardial ischemia/reperfusion through a vagus nerve-mediated mechanism. *European Journal of Pharmacology*, **2010**, 637, 124-30 | 5.3 | 34 |
| 58 | Effects of aglycone genistein in a rat experimental model of postmenopausal metabolic syndrome. *Journal of Endocrinology*, **2009**, 200, 367-76 | 4.7 | 45 |
| 57 | Vagus nerve mediates the protective effects of melanocortins against cerebral and systemic damage after ischemic stroke. *Journal of Cerebral Blood Flow and Metabolism*, **2009**, 29, 512-23 | 7.3 | 82 |
| 56 | Functional recovery after delayed treatment of ischemic stroke with melanocortins is associated with overexpression of the activity-dependent gene Zif268. *Brain, Behavior, and Immunity*, **2009**, 23, 844-50 | 16.6 | 30 |
| 55 | Effects of chronic desipramine treatment on alpha2-adrenoceptors and mu-opioid receptors in the guinea pig cortex and hippocampus. *European Journal of Pharmacology*, **2008**, 579, 116-25 | 5.3 | 12 |
| 54 | Selective melanocortin MC4 receptor agonists reverse haemorrhagic shock and prevent multiple organ damage. *British Journal of Pharmacology*, **2007**, 150, 595-603 | 8.6 | 38 |
| 53 | Neuroprotection in focal cerebral ischemia owing to delayed treatment with melanocortins. *European Journal of Pharmacology*, **2007**, 570, 57-65 | 5.3 | 39 |
| 52 | The disaccharide trehalose inhibits proinflammatory phenotype activation in macrophages and prevents mortality in experimental septic shock. *Shock*, **2007**, 27, 91-6 | 3.4 | 39 |
| 51 | Broad therapeutic treatment window of [Nle(4), D-Phe(7)]alpha-melanocyte-stimulating hormone for long-lasting protection against ischemic stroke, in Mongolian gerbils. *European Journal of Pharmacology*, **2006**, 538, 48-56 | 5.3 | 33 |
| 50 | Both early and delayed treatment with melanocortin 4 receptor-stimulating melanocortins produces neuroprotection in cerebral ischemia. *Endocrinology*, **2006**, 147, 1126-35 | 4.8 | 100 |
| 49 | Functional interaction between alpha2-adrenoceptors, mu- and kappa-opioid receptors in the guinea pig myenteric plexus: effect of chronic desipramine treatment. *European Journal of Pharmacology*, **2006**, 553, 269-79 | 5.3 | 6 |

| | | | |
|---|---|---|---|
| 48 | Recombinant human erythropoietin improves angiogenesis and wound healing in experimental burn wounds. *Critical Care Medicine*, **2006**, 34, 1139-46 | 1.4 | 106 |
| 47 | Activation of the cholinergic anti-inflammatory pathway reduces NF-kappab activation, blunts TNF-alpha production, and protects againts splanchic artery occlusion shock. *Shock*, **2006**, 25, 500-6 | 3.4 | 81 |
| 46 | Activation of an efferent cholinergic pathway produces strong protection against myocardial ischemia/reperfusion injury in rats. *Critical Care Medicine*, **2005**, 33, 2621-8 | 1.4 | 139 |
| 45 | Adrenocorticotropin reverses hemorrhagic shock in anesthetized rats through the rapid activation of a vagal anti-inflammatory pathway. *Cardiovascular Research*, **2004**, 63, 357-65 | 9.9 | 104 |
| 44 | Effect of late treatment with gamma-hydroxybutyrate on the histological and behavioral consequences of transient brain ischemia in the rat. *European Journal of Pharmacology*, **2004**, 485, 183-91 | 5.3 | 16 |
| 43 | Effect of sumatriptan in different models of pain in rats. *European Journal of Pharmacology*, **2004**, 497, 181-6 | 5.3 | 16 |
| 42 | Effects of ketamine anesthesia on central nociceptive processing in the rat: a 2-deoxyglucose study. *Neuroscience*, **2004**, 125, 485-94 | 3.9 | 10 |
| 41 | Further evidence that melanocortins prevent myocardial reperfusion injury by activating melanocortin MC3 receptors. *European Journal of Pharmacology*, **2003**, 477, 227-34 | 5.3 | 35 |
| 40 | Independent time courses of supraspinal nociceptive activity and spinally mediated behavior during tonic pain. *Pain*, **2003**, 104, 291-301 | 8 | 30 |
| 39 | Efferent vagal fibre stimulation blunts nuclear factor-kappaB activation and protects against hypovolemic hemorrhagic shock. *Circulation*, **2003**, 107, 1189-94 | 16.7 | 254 |
| 38 | Modulatory activity of sildenafil on copulatory behaviour of both intact and castrated male rats. *Pharmacology Biochemistry and Behavior*, **2002**, 72, 717-22 | 3.9 | 23 |
| 37 | MC(3) receptors are involved in the protective effect of melanocortins in myocardial ischemia/reperfusion-induced arrhythmias. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2002**, 366, 177-82 | 3.4 | 34 |
| 36 | Influence of sildenafil on central dopamine-mediated behaviour in male rats. *Life Sciences*, **2002**, 70, 1501-8 | 6.8 | 34 |
| 35 | Influence of sildenafil on copulatory behaviour in sluggish or normal ejaculator male rats: a central dopamine mediated effect?. *Neuropharmacology*, **2002**, 42, 562-7 | 5.5 | 35 |
| 34 | Neuroleptic-like profile of the cannabinoid agonist, HU 210, on rodent behavioural models. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2002**, 26, 91-6 | 5.5 | 7 |
| 33 | Hu 210: a potent tool for investigations of the cannabinoid system. *CNS Neuroscience & Therapeutics*, **2001**, 7, 131-45 | | 37 |
| 32 | Effects of the cannabinoid receptor agonist, HU 210, on ingestive behaviour and body weight of rats. *European Journal of Pharmacology*, **2000**, 391, 275-9 | 5.3 | 37 |
| 31 | Inhibitory effects of the cannabinoid agonist HU 210 on rat sexual behaviour. *Physiology and Behavior*, **2000**, 69, 547-54 | 3.5 | 46 |

| | | | |
|---|---|---|---|
| 30 | CNS pattern of metabolic activity during tonic pain: evidence for modulation by beta-endorphin. *European Journal of Neuroscience*, **1999**, 11, 874-88 | 3.5 | 55 |
| 29 | Cannabimimetic activity in rats and pigeons of HU 210, a potent antiemetic drug. *Pharmacology Biochemistry and Behavior*, **1999**, 62, 75-80 | 3.9 | 42 |
| 28 | Learning impairment produced in rats by the cannabinoid agonist HU 210 in a water-maze task. *Pharmacology Biochemistry and Behavior*, **1999**, 64, 555-61 | 3.9 | 103 |
| 27 | Influence of the cannabinoid agonist HU 210 on cocaine- and CQP 201-403-induced behavioural effects in rat. *Life Sciences*, **1999**, 65, 823-31 | 6.8 | 33 |
| 26 | Effects of (-)eticlopride and 7-OH-DPAT on the tail-suspension test in mice. *Journal of Psychopharmacology*, **1997**, 11, 339-44 | 4.6 | 14 |
| 25 | Involvement of dopamine D2 receptors in the effect of cocaine on sexual behaviour and stretching-yawning of male rats. *Neuropharmacology*, **1997**, 36, 769-77 | 5.5 | 20 |
| 24 | Involvement of dopamine receptors in the antipsychotic profile of (-) eticlopride. *Physiology and Behavior*, **1997**, 61, 563-7 | 3.5 | 12 |
| 23 | Synthesis, resolution, and preliminary evaluation of trans-2-amino-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes and related derivatives as dopamine receptors ligands. *Journal of Medicinal Chemistry*, **1996**, 39, 4238-46 | 8.3 | 11 |
| 22 | Behavioral effects induced by the dopamine D3 agonist 7-OH-DPAT in sexually-active and -inactive male rats. *Neuropharmacology*, **1996**, 35, 279-84 | 5.5 | 30 |
| 21 | Influence of eticlopride on cocaine- and DA D2 agonist-induced behavioral effects in rats. *Pharmacology Biochemistry and Behavior*, **1996**, 53, 525-30 | 3.9 | 19 |
| 20 | Sexual attraction and copulation in male rats: effects of the dopamine agonist SND 919. *Pharmacology Biochemistry and Behavior*, **1995**, 50, 29-34 | 3.9 | 24 |
| 19 | Behavioural effects of the dopamine D3 receptor agonist 7-OH-DPAT in rats. *Pharmacological Research*, **1995**, 32, 63-8 | 10.2 | 13 |
| 18 | Behavioural assessment in rats of the antipsychotic potential of the potent dopamine D2 receptor antagonist, (-)eticlopride. *Pharmacological Research*, **1995**, 31, 261-7 | 10.2 | 21 |
| 17 | Inability of (-)deprenyl to modify copulatory performance in the male rat, whether or not stimulated by the selective D2 dopamine agonist SND 919. *Pharmacological Research*, **1994**, 29, 373-82 | 10.2 | 1 |
| 16 | Effect on rat feeding behavior of two selective D2 dopamine agonists. *Physiology and Behavior*, **1994**, 56, 921-6 | 3.5 | 2 |
| 15 | The selective D2 dopamine receptor antagonist eticlopride counteracts the ejaculatio praecox induced by the selective D2 dopamine agonist SND 919 in the rat. *Life Sciences*, **1994**, 55, 1155-62 | 6.8 | 28 |
| 14 | Influence of idazoxan on the dopamine D2 receptor agonist-induced behavioural effects in rats. *European Journal of Pharmacology*, **1993**, 250, 51-7 | 5.3 | 18 |
| 13 | Behavioural profile in the chicken of CQ 32-084 and CQP 201-403, two dopamine agonists. *Pharmacology Biochemistry and Behavior*, **1993**, 45, 117-22 | 3.9 | 6 |

| | | | |
|---|---|---|---|
| 12 | Behavioural evidence that different neurochemical mechanisms underly stretching-yawning and penile erection induced in male rats by SND 919, a new selective D2 dopamine receptor agonist. *Psychopharmacology*, **1993**, 113, 172-6 | 4.7 | 34 |
| 11 | Behavioural effects induced in rats and chicks by D2 dopamine agonists. *Physiology and Behavior*, **1993**, 54, 695-700 | 3.5 | 17 |
| 10 | Effect of the D2-autoreceptor agonist B-HT 958 on both spontaneous and ACTH-induced stretching, yawning and grooming in the rat. *Life Sciences*, **1992**, 50, 1013-9 | 6.8 | 6 |
| 9 | The D2 agonist B-HT 920 potently antagonizes rat grooming. *Pharmacological Research*, **1992**, 25, 29-30 | 10.2 | 2 |
| 8 | A comparative study of B-HT 920 and diazepam in the X-maze feeding test. *Pharmacological Research*, **1992**, 25 Suppl 1, 49-50 | 10.2 | 4 |
| 7 | B-HT 920-induced effects on rat feeding behaviour. *Pharmacological Research*, **1992**, 26, 285-92 | 10.2 | 7 |
| 6 | Grooming and stretching yawning: two behavioural pointers of D2 dopamine receptor agonistic effect. *Pharmacological Research*, **1992**, 25, 35-36 | 10.2 | |
| 5 | Suppressive effect of the dopamine D2 receptor agonist B-HT 920 on rat grooming. *European Journal of Pharmacology*, **1992**, 216, 345-50 | 5.3 | 8 |
| 4 | B-HT 920 stimulates feeding and antagonizes anorexia induced by ACTH and immobilisation. *European Journal of Pharmacology*, **1992**, 210, 17-22 | 5.3 | 17 |
| 3 | Effects of the dopamine D2 agonists lisuride and CQ 32-084 on rat feeding behaviour. *Pharmacology Biochemistry and Behavior*, **1992**, 41, 683-8 | 3.9 | 14 |
| 2 | NPY-induced inhibition of male copulatory activity is a direct behavioural effect. *Neuropeptides*, **1990**, 16, 169-72 | 3.3 | 33 |
| 1 | Influence of ACTH-(1–4) on ingestive behaviours. *Pharmacological Research*, **1989**, 21, 467-468 | 10.2 | |